Abstract Topics
Click the Theme names below to expand a full list of available topics.
Theme A: β-Amyloid Diseases
| Theme A: β-Amyloid Diseases / A01.a. Disease Mechanisms, Pathophysiology: Abeta aggregation, protein misfolding |
| Theme A: β-Amyloid Diseases / A01.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like |
| Theme A: β-Amyloid Diseases / A01.c. Disease Mechanisms, Pathophysiology: Inflammation |
| Theme A: β-Amyloid Diseases / A01.d. Disease Mechanisms, Pathophysiology: Synaptic plastcity & synapse pathology |
| Theme A: β-Amyloid Diseases / A01.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium |
| Theme A: β-Amyloid Diseases / A01.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress, chaperones |
| Theme A: β-Amyloid Diseases / A01.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage |
| Theme A: β-Amyloid Diseases / A01.h. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking |
| Theme A: β-Amyloid Diseases / A01.i. Disease Mechanisms, Pathophysiology: Microglia |
| Theme A: β-Amyloid Diseases / A01.j. Disease Mechanisms, Pathophysiology: Astroglia |
| Theme A: β-Amyloid Diseases / A01.k. Disease Mechanisms, Pathophysiology: Neurogenesis |
| Theme A: β-Amyloid Diseases / A01.l. Disease Mechanisms, Pathophysiology: Vasculature, microbleeds, hypertension, angiogenesis |
| Theme A: β-Amyloid Diseases / A01.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier |
| Theme A: β-Amyloid Diseases / A01.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin |
| Theme A: β-Amyloid Diseases / A01.o. Disease Mechanisms, Pathophysiology: Neural networks, plasticity |
| Theme A: β-Amyloid Diseases / A01.p. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs |
| Theme A: β-Amyloid Diseases / A01.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death |
| Theme A: β-Amyloid Diseases / A01.r. Disease Mechanisms, Pathophysiology: Aging |
| Theme A: β-Amyloid Diseases / A01.s. Disease Mechanisms, Pathophysiology: Microbiome |
| Theme A: β-Amyloid Diseases / A01.t. Disease Mechanisms, Pathophysiology: Cholinergic |
| Theme A: β-Amyloid Diseases / A02.a. Therapeutic Targets, Mechanisms for Treatment: Abeta, truncated & pGlu-Abeta |
| Theme A: β-Amyloid Diseases / A02.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy |
| Theme A: β-Amyloid Diseases / A02.c. Therapeutic Targets, Mechanisms for Treatment: Secretases, proteases |
| Theme A: β-Amyloid Diseases / A02.d. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes |
| Theme A: β-Amyloid Diseases / A02.e. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based, GLP-1 receptor-based |
| Theme A: β-Amyloid Diseases / A02.f. Therapeutic Targets, Mechanisms for Treatment: ApoE & lipoprotein-based |
| Theme A: β-Amyloid Diseases / A02.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory |
| Theme A: β-Amyloid Diseases / A02.h. Therapeutic Targets, Mechanisms for Treatment: Anti-oxidants |
| Theme A: β-Amyloid Diseases / A02.i. Therapeutic Targets, Mechanisms for Treatment: Neurotrophic, synaptic plasticity, repair, regenerative medicine |
| Theme A: β-Amyloid Diseases / A02.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones |
| Theme A: β-Amyloid Diseases / A02.k. Therapeutic Targets, Mechanisms for Treatment: TREM2 |
| Theme A: β-Amyloid Diseases / A02.l. Therapeutic Targets, Mechanisms for Treatment: CD33 |
| Theme A: β-Amyloid Diseases / A02.m. Therapeutic Targets, Mechanisms for Treatment: Microglia |
| Theme A: β-Amyloid Diseases / A02.n. Therapeutic Targets, Mechanisms for Treatment: Astroglia |
| Theme A: β-Amyloid Diseases / A02.o. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing |
| Theme A: β-Amyloid Diseases / A02.p. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi |
| Theme A: β-Amyloid Diseases / A02.r. Therapeutic Targets, Mechanisms for Treatment: Other |
| Theme A: β-Amyloid Diseases / A03.a. Drug Development, Clinical Trials: Immunotherapy |
| Theme A: β-Amyloid Diseases / A03.c. Drug Development, Clinical Trials: Amyloid clearance |
| Theme A: β-Amyloid Diseases / A03.d. Drug Development, Clinical Trials: Secretase inhibitors & modulators |
| Theme A: β-Amyloid Diseases / A03.e. Drug Development, Clinical Trials: Aggregation inhibitors |
| Theme A: β-Amyloid Diseases / A03.f. Drug Development, Clinical Trials: Neuroprotective & mitochondrial compounds |
| Theme A: β-Amyloid Diseases / A03.g. Drug Development, Clinical Trials: Neurotransmitter-based agonists and modulators, GLP-1 receptor agonists |
| Theme A: β-Amyloid Diseases / A03.k. Drug Development, Clinical Trials: Transcranial magnetic stimulation |
| Theme A: β-Amyloid Diseases / A03.l. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing |
| Theme A: β-Amyloid Diseases / A03.o. Drug Development, Clinical Trials:New clinical trial designs; Simulation of progress-digital twins |
| Theme A: β-Amyloid Diseases / A03.p. Drug Development, Clinical Trials: Non-pharmacological interventions |
| Theme A: β-Amyloid Diseases / A04.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy |
| Theme A: β-Amyloid Diseases / A04.b. Imaging, Biomarkers, Diagnostics: Functional MRI |
| Theme A: β-Amyloid Diseases / A04.c. Imaging, Biomarkers, Diagnostics: PET – amyloid |
| Theme A: β-Amyloid Diseases / A04.d. Imaging, Biomarkers, Diagnostics: PET – glucose |
| Theme A: β-Amyloid Diseases / A04.e. Imaging, Biomarkers, Diagnostics: PET – other |
| Theme A: β-Amyloid Diseases / A04.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging |
| Theme A: β-Amyloid Diseases / A04.h. Imaging, Biomarkers, Diagnostics: body fluids, CSF-, and blood-based biomarkers |
| Theme A: β-Amyloid Diseases / A04.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG |
| Theme A: β-Amyloid Diseases / A04.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests, Digital endpoints, remote testing |
| Theme A: β-Amyloid Diseases / A04.k. Imaging, Biomarkers, Diagnostics: Other |
| Theme A: β-Amyloid Diseases / A05.a. Genetics, Epidemiology: Whole genome sequencing |
| Theme A: β-Amyloid Diseases / A05.b. Genetics, Epidemiology: Disease-causing mutations |
| Theme A: β-Amyloid Diseases / A05.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes |
| Theme A: β-Amyloid Diseases / A05.e. Genetics, Epidemiology: Aging |
| Theme A: β-Amyloid Diseases / A05.f. Genetics, Epidemiology: Environmental risk factors |
| Theme A: β-Amyloid Diseases / A05.g. Genetics, Epidemiology: Metabolic and cardiovascular |
| Theme A: β-Amyloid Diseases / A05.h. Genetics, Epidemiology: Infectious and inflammation |
| Theme A: β-Amyloid Diseases / A05.i. Genetics, Epidemiology: Other |
| Theme A: β-Amyloid Diseases / A06.a. Cell, Molecular and Systems Biology: APP, APLP, Abeta |
| Theme A: β-Amyloid Diseases / A06.b. Cell, Molecular and Systems Biology: ApoE |
| Theme A: β-Amyloid Diseases / A06.c. Cell, Molecular and Systems Biology: Secretases |
| Theme A: β-Amyloid Diseases / A06.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations |
| Theme A: β-Amyloid Diseases / A06.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics |
| Theme A: β-Amyloid Diseases / A06.h. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation |
| Theme A: β-Amyloid Diseases / A06.i. Cell, Molecular and Systems Biology: Other |
| Theme A: β-Amyloid Diseases / A07.a. Animal Models: Transgenic rodents |
| Theme A: β-Amyloid Diseases / A07.b. Animal Models: Primates, naturally occuring models and brain organoids |
| Theme A: β-Amyloid Diseases / A07.c. Animal Models: Non-mamalian models, Other |
Theme B: Taupathies
| Theme B: Taupathies / B01.a. Disease Mechanisms, Pathophysiology: Tau aggregation, phophorylation, acetylation & modifications |
| Theme B: Taupathies / B01.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like |
| Theme B: Taupathies / B01.c. Disease Mechanisms, Pathophysiology: Inflammation |
| Theme B: Taupathies / B01.d. Disease Mechanisms, Pathophysiology: Synapse pathology |
| Theme B: Taupathies / B01.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium |
| Theme B: Taupathies / B01.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress |
| Theme B: Taupathies / B01.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage |
| Theme B: Taupathies / B01.i. Disease Mechanisms, Pathophysiology: Microglia |
| Theme B: Taupathies / B01.j. Disease Mechanisms, Pathophysiology: Astroglia |
| Theme B: Taupathies / B01.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier |
| Theme B: Taupathies / B01.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin |
| Theme B: Taupathies / B01.o. Disease Mechanisms, Pathophysiology: Neural networks & plasticity |
| Theme B: Taupathies / B01.p. Disease Mechanisms, Pathophysiology: transcriptional & translational regulation, micro RNAs |
| Theme B: Taupathies / B01.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death |
| Theme B: Taupathies / B01.s. Disease Mechanisms, Pathophysiology: Aging |
| Theme B: Taupathies / B01.u. Disease Mechanisms, Pathophysiology: Other |
| Theme B: Taupathies / B02.a. Therapeutic Targets, Mechanisms for Treatment: Tau, phosphorylation, truncation |
| Theme B: Taupathies / B02.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy |
| Theme B: Taupathies / B02.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, phosphatases, other enzymes |
| Theme B: Taupathies / B02.d. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based, GLP-1 receptor-based |
| Theme B: Taupathies / B02.e. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory |
| Theme B: Taupathies / B02.h. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, NFT, misfolding, chaperones |
| Theme B: Taupathies / B02.i. Therapeutic Targets, Mechanisms for Treatment: Gene and RNAi therapy |
| Theme B: Taupathies / B02.j. Therapeutic Targets, Mechanisms for Treatment: Microglia |
| Theme B: Taupathies / B02.m. Therapeutic Targets, Mechanisms for Treatment: Other |
| Theme B: Taupathies / B03.a. Drug Development, Clinical Trials: Immunotherapy |
| Theme B: Taupathies / B03.c. Drug Development, Clinical Trials: tau clearance |
| Theme B: Taupathies / B03.e. Drug Development, Clinical Trials: Aggregation inhibitors |
| Theme B: Taupathies / B03.m. Drug Development, Clinical Trials: New clinical trial designs; Simulation of progress-digital twins |
| Theme B: Taupathies / B04.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy |
| Theme B: Taupathies / B04.c. Imaging, Biomarkers, Diagnostics: PET – tau |
| Theme B: Taupathies / B04.d. Imaging, Biomarkers, Diagnostics: PET – glucose |
| Theme B: Taupathies / B04.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging |
| Theme B: Taupathies / B04.h. Imaging, Biomarkers, Diagnostics: body fluids, CSF- and blood-based biomarkers |
| Theme B: Taupathies / B04.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG |
| Theme B: Taupathies / B04.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests, Digital endpoints, remote testing |
| Theme B: Taupathies / B04.k. Imaging, Biomarkers, Diagnostics: Other |
| Theme B: Taupathies / B05.g. Genetics, Epidemiology: Other |
| Theme B: Taupathies / B06.a. Cell, Molecular and Systems Biology: Tau, tau isoforms |
| Theme B: Taupathies / B06.d. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity |
| Theme B: Taupathies / B06.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations |
| Theme B: Taupathies / B06.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics |
| Theme B: Taupathies / B07.a. Animal Models: Transgenic rodents |
| Theme B: Taupathies / B07.b. Animal Models: Primates, naturally occuring models and brain organoids |
Theme C: α-Synucleinopathies
| Theme C: α-Synucleinopathies / C01.a. Disease Mechanisms, Pathophysiology: a-synuclein aggregation |
| Theme C: α-Synucleinopathies / C01.b. Disease Mechanisms, Pathophysiology: LRKK2, parkin, PINK1, DJ-1 |
| Theme C: α-Synucleinopathies / C01.c. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like |
| Theme C: α-Synucleinopathies / C01.d. Disease Mechanisms, Pathophysiology: Autophagy, lysosomes, ubiquitin, proteasome |
| Theme C: α-Synucleinopathies / C01.e. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking |
| Theme C: α-Synucleinopathies / C01.f. Disease Mechanisms, Pathophysiology: Inflammation |
| Theme C: α-Synucleinopathies / C01.g. Disease Mechanisms, Pathophysiology: Microglia |
| Theme C: α-Synucleinopathies / C01.h. Disease Mechanisms, Pathophysiology: Astroglia |
| Theme C: α-Synucleinopathies / C01.i. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium |
| Theme C: α-Synucleinopathies / C01.i. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage |
| Theme C: α-Synucleinopathies / C01.k. Disease Mechanisms, Pathophysiology: Synapse pathology, neural networks, plasticity, neurogenesis |
| Theme C: α-Synucleinopathies / C01.l. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs |
| Theme C: α-Synucleinopathies / C01.n. Disease Mechanisms, Pathophysiology: Protein aggregation, misfolding, chaperones |
| Theme C: α-Synucleinopathies / C01.o. Disease Mechanisms, Pathophysiology: Metal ions |
| Theme C: α-Synucleinopathies / C01.p. Disease Mechanisms, Pathophysiology: Modeling of disease progression |
| Theme C: α-Synucleinopathies / C01.q. Disease Mechanisms, Pathophysiology: Dopaminergic, Cholinergic |
| Theme C: α-Synucleinopathies / C01.r. Disease Mechanisms, Pathophysiology: Others |
| Theme C: α-Synucleinopathies / C02.a. Therapeutic Targets, Mechanisms for Treatment: a-synuclein |
| Theme C: α-Synucleinopathies / C02.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy |
| Theme C: α-Synucleinopathies / C02.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes |
| Theme C: α-Synucleinopathies / C02.d. Therapeutic Targets, Mechanisms for Treatment: Dopamine, Acetylcholine, neurotransmitters, GLP-1 receptor |
| Theme C: α-Synucleinopathies / C02.e. Therapeutic Targets, Mechanisms for Treatment: Cell transplantation |
| Theme C: α-Synucleinopathies / C02.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory, anti-oxidant |
| Theme C: α-Synucleinopathies / C02.h. Therapeutic Targets, Mechanisms for Treatment: Microglia |
| Theme C: α-Synucleinopathies / C02.i. Therapeutic Targets, Mechanisms for Treatment:Astroglia |
| Theme C: α-Synucleinopathies / C02.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones |
| Theme C: α-Synucleinopathies / C02.k. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing |
| Theme C: α-Synucleinopathies / C02.l. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi |
| Theme C: α-Synucleinopathies / C02.m. Therapeutic Targets, Mechanisms for Treatment: neurogenesis and iPSC |
| Theme C: α-Synucleinopathies / C02.n. Therapeutic Targets, Mechanisms for Treatment: Other |
| Theme C: α-Synucleinopathies / C03.a. Drug Development, Clinical Trials: Immunotherapy |
| Theme C: α-Synucleinopathies / C03.b. Drug Development, Clinical Trials: Vitamins, antioxidants, neuroprotective compounds |
| Theme C: α-Synucleinopathies / C03.c. Drug Development, Clinical Trials: Neurotransmitter-based agonists and modulators, GLP-1 receptor agonists |
| Theme C: α-Synucleinopathies / C03.e. Drug Development, Clinical Trials: Aggregation inhibitors |
| Theme C: α-Synucleinopathies / C03.f. Drug Development, Clinical Trials: Enzyme modulators |
| Theme C: α-Synucleinopathies / C03.h. Drug Development, Clinical Trials: Drug delivery systems |
| Theme C: α-Synucleinopathies / C03.i. Drug Development, Clinical Trials: Non-pharmacological interventions, neurosurgery |
| Theme C: α-Synucleinopathies / C04.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy |
| Theme C: α-Synucleinopathies / C04.b. Imaging, Biomarkers, Diagnostics: Functional MRI |
| Theme C: α-Synucleinopathies / C04.c. Imaging, Biomarkers, Diagnostics: PET |
| Theme C: α-Synucleinopathies / C04.d. Imaging, Biomarkers, Diagnostics: SPECT |
| Theme C: α-Synucleinopathies / C04.e. Imaging, Biomarkers, Diagnostics: Multimodal imaging |
| Theme C: α-Synucleinopathies / C04.f. Imaging, Biomarkers, Diagnostics: skin, body fluids, CSF-, and blood-based biomarkers |
| Theme C: α-Synucleinopathies / C04.g. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG |
| Theme C: α-Synucleinopathies / C04.h. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric, behavioral and motor tests |
| Theme C: α-Synucleinopathies / C04.j. Imaging, Biomarkers, Diagnostics: Other |
| Theme C: α-Synucleinopathies / C05.a. Genetics, Epidemiology: Whole genome sequencing |
| Theme C: α-Synucleinopathies / C05.b. Genetics, Epidemiology: Disease-causing mutations |
| Theme C: α-Synucleinopathies / C05.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes |
| Theme C: α-Synucleinopathies / C05.d. Genetics, Epidemiology: Aging |
| Theme C: α-Synucleinopathies / C05.g. Genetics, Epidemiology: Other |
| Theme C: α-Synucleinopathies / C06.a. Cell, Molecular and Systems Biology: a-synuclein |
| Theme C: α-Synucleinopathies / C06.b. Cell, Molecular and Systems Biology: LRKK2, parkin, PINK1, DJ-1 and other PD realted genes |
| Theme C: α-Synucleinopathies / C06.e. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations |
| Theme C: α-Synucleinopathies / C06.f. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics |
| Theme C: α-Synucleinopathies / C06.g. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation |
| Theme C: α-Synucleinopathies / C06.h. Cell, Molecular and Systems Biology: Other |
| Theme C: α-Synucleinopathies / C07.a. Animal Models: Transgenic rodents |
| Theme C: α-Synucleinopathies / C07.b. Animal Models: Primates, naturally occuring models and brain organoids |
Theme D: TDP43, TMEM106B and C9orf72-Related Diseases
| Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D01. Disease Mechanisms, Pathophysiology |
| Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D02. Therapeutic Targets, Mechanisms for Treatment |
| Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D04. Imaging, Biomarkers, Diagnostics |
| Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D05. Genetics, Epidemiology |
| Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D06. Cell, Molecular and Systems Biology |
| Theme D: TDP43, TMEM106B and C9orf72-Related Diseases / D07. Animal Models |
Theme E: Vascular Diseases
| Theme E : Vascular Diseases / E01. Disease Mechanisms, Pathophysiology |
| Theme E : Vascular Diseases / E02. Therapeutic Targets, Mechanisms for Treatment |
| Theme E : Vascular Diseases / E04. Imaging, Biomarkers, Diagnostics |
| Theme E : Vascular Diseases / E05. Genetics, Epidemiology |
| Theme E : Vascular Diseases / E06. Cell, Molecular and Systems Biology |
| Theme E : Vascular Diseases / E07. Animal Models |
Theme F: Prion Diseases
| Theme F: Prion Diseases / F01. Disease Mechanisms, Pathophysiology |
| Theme F: Prion Diseases / F02. Therapeutic Targets, Mechanisms for Treatment |
| Theme F: Prion Diseases / F04. Imaging, Biomarkers, Diagnostics |
Theme G: Huntington's and Other Neurodegenerative Diseases
| Theme G: Huntington\’s and Other Neurodegenerative Diseases / G01. Disease Mechanisms, Pathophysiology |
| Theme G: Huntington\’s and Other Neurodegenerative Diseases / G02. Therapeutic Targets, Mechanisms for Treatment |
| Theme G: Huntington\’s and Other Neurodegenerative Diseases / G03. Drug Development, Clinical Trials |
| Theme G: Huntington\’s and Other Neurodegenerative Diseases / G04. Imaging, Biomarkers, Diagnostics |
| Theme G: Huntington\’s and Other Neurodegenerative Diseases / G05. Genetics, Epidemiology |
| Theme G: Huntington\’s and Other Neurodegenerative Diseases / G06. Cell, Molecular and Systems Biology |
| Theme G: Huntington\’s and Other Neurodegenerative Diseases / G07. Animal Models |
Theme H: Demyelinating Diseases
| Theme H: Demyelinating Diseases / H02. Therapeutic Targets, Mechanisms for Treatment |
| Theme H: Demyelinating Diseases / H04. Imaging, Biomarkers, Diagnostics |
| Theme H: Demyelinating Diseases / H07. Animal Models |
Theme I: Lysosomal Storage Diseases
| Theme I: Lysosomal Storage Diseases / I01. Disease Mechanisms, Pathophysiology |
| Theme I: Lysosomal Storage Diseases / I02. Therapeutic Targets, Mechanisms for Treatment |
| Theme I: Lysosomal Storage Diseases / I07. Animal Models and brain organoids |
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases
| Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J01. Disease Mechanisms, Pathophysiology |
| Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J02. Therapeutic Targets, Mechanisms for Treatment |
| Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J03. Drug Development, Clinical Trials |
| Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J04. Imaging, Biomarkers, Diagnostics |
| Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J05. Genetics, Epidemiology |
| Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J06. Cell, Molecular and Systems Biology |
| Theme J: Psychiatric Symptoms in Neurodegenerative Diseases / J07. Animal Models |
Theme K: Patient Care and Support
| Theme K: Patient Care and Support / K01.a. Dementia and Cognitive Dysfunction: Caregiver support |
| Theme K: Patient Care and Support / K01.b. Dementia and Cognitive Dysfunction: Mobile applications, social networks |
| Theme K: Patient Care and Support / K01.c. Dementia and Cognitive Dysfunction: Cognitive training |
| Theme K: Patient Care and Support / K01.e. Dementia and Cognitive Dysfunction: Support devices & monitoring |
| Theme K: Patient Care and Support / K01.f. Dementia and Cognitive Dysfunction: Quality of life |
| Theme K: Patient Care and Support / K01.h. Dementia and Cognitive Dysfunction: Behavioral & psychiatric symptoms |
| Theme K: Patient Care and Support / K01.j. Dementia and Cognitive Dysfunction: Other |
| Theme K: Patient Care and Support / K02.a. Movement Disorders: Caregiver support |
| Theme K: Patient Care and Support / K02.c. Movement Disorders: Motor coordination & exercise |
| Theme K: Patient Care and Support / K02.d. Movement Disorders: Support devices & monitoring |
| Theme K: Patient Care and Support / K02.f. Movement Disorders: Quality of life |
| Theme K: Patient Care and Support / K02.g. Movement Disorders: Behavioral & psychiatric symptoms |
| Theme K: Patient Care and Support / K02.h. Movement Disorders: Other |
Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases.
| Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01a. Neuropathology of Covid-19 |
| Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01b. Neuroimaging of Covid-19 |
| Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01c. Neurological manifestations of Covid-19 |
| Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01d. Comorbidity of Neurodegeneration with Covid-19 |
| Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01f. CNS invasion of SARS-CoV2 |
| Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases / L01g. Epidemiology of Covid-19 in Patients with Neurodegenerative Diseases |